US Stock MarketDetailed Quotes

CMMB Chemomab Therapeutics

Watchlist
  • 1.630
  • -0.060-3.55%
Trading Dec 13 11:27 ET
30.74MMarket Cap-1.73P/E (TTM)

Chemomab Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-15.04%3.71M
-54.02%3.77M
-55.27%4.05M
-10.77%25.46M
-55.47%3.85M
-47.49%4.37M
31.04%8.2M
70.09%9.05M
130.72%28.53M
72.01%8.64M
Selling and administrative expenses
-11.72%874K
-73.54%840K
-56.71%936K
-38.75%7.08M
-72.66%751K
-65.79%990K
-4.94%3.18M
-16.04%2.16M
91.55%11.56M
4.01%2.75M
-General and administrative expense
-11.72%874K
-73.54%840K
-56.71%936K
-38.75%7.08M
-72.66%751K
-65.79%990K
-4.94%3.18M
-16.04%2.16M
91.55%11.56M
4.01%2.75M
Research and development costs
-16.02%2.84M
-41.67%2.93M
-54.81%3.11M
8.27%18.38M
-47.46%3.1M
-37.73%3.38M
72.27%5.02M
150.89%6.89M
168.03%16.98M
147.38%5.9M
Operating profit
15.04%-3.71M
54.02%-3.77M
55.27%-4.05M
10.77%-25.46M
55.47%-3.85M
47.49%-4.37M
-31.04%-8.2M
-70.09%-9.05M
-130.72%-28.53M
-72.01%-8.64M
Net non-operating interest income expense
-1.73%227K
-47.10%137K
-43.22%180K
250.71%1.24M
13.42%431K
-2.53%231K
153.96%259K
46.76%317K
418.02%353K
3,266.67%380K
Total other finance cost
1.73%-227K
47.10%-137K
43.22%-180K
-250.71%-1.24M
-13.42%-431K
2.53%-231K
-153.96%-259K
-46.76%-317K
-418.02%-353K
-3,266.67%-380K
Other net income (expense)
Income before tax
15.79%-3.48M
54.25%-3.63M
55.70%-3.87M
14.05%-24.22M
58.64%-3.42M
48.81%-4.14M
-17.85%-7.94M
-71.08%-8.73M
-125.84%-28.18M
-64.06%-8.26M
Income tax
0
0
0
0
0
-55K
106.25%34K
21K
-534K
10K
Net income
14.65%-3.48M
54.44%-3.63M
55.81%-3.87M
12.39%-24.22M
58.69%-3.42M
49.49%-4.08M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
-64.26%-8.27M
Net income continuous Operations
14.65%-3.48M
54.44%-3.63M
55.81%-3.87M
12.39%-24.22M
58.69%-3.42M
49.49%-4.08M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
-64.26%-8.27M
Minority interest income
Net income attributable to the parent company
14.65%-3.48M
54.44%-3.63M
55.81%-3.87M
12.39%-24.22M
58.69%-3.42M
49.49%-4.08M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
-64.26%-8.27M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
14.65%-3.48M
54.44%-3.63M
55.81%-3.87M
12.39%-24.22M
58.69%-3.42M
49.49%-4.08M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
-64.26%-8.27M
Basic earnings per share
41.18%-0.2
63.89%-0.26
65.00%-0.28
14.88%-2.06
69.44%-0.22
51.43%-0.34
-33.33%-0.72
-81.82%-0.8
-101.67%-2.42
-63.64%-0.72
Diluted earnings per share
41.18%-0.2
63.89%-0.26
65.00%-0.28
14.88%-2.06
69.44%-0.22
51.43%-0.34
-33.33%-0.72
-81.82%-0.8
-101.67%-2.42
-63.64%-0.72
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -15.04%3.71M-54.02%3.77M-55.27%4.05M-10.77%25.46M-55.47%3.85M-47.49%4.37M31.04%8.2M70.09%9.05M130.72%28.53M72.01%8.64M
Selling and administrative expenses -11.72%874K-73.54%840K-56.71%936K-38.75%7.08M-72.66%751K-65.79%990K-4.94%3.18M-16.04%2.16M91.55%11.56M4.01%2.75M
-General and administrative expense -11.72%874K-73.54%840K-56.71%936K-38.75%7.08M-72.66%751K-65.79%990K-4.94%3.18M-16.04%2.16M91.55%11.56M4.01%2.75M
Research and development costs -16.02%2.84M-41.67%2.93M-54.81%3.11M8.27%18.38M-47.46%3.1M-37.73%3.38M72.27%5.02M150.89%6.89M168.03%16.98M147.38%5.9M
Operating profit 15.04%-3.71M54.02%-3.77M55.27%-4.05M10.77%-25.46M55.47%-3.85M47.49%-4.37M-31.04%-8.2M-70.09%-9.05M-130.72%-28.53M-72.01%-8.64M
Net non-operating interest income expense -1.73%227K-47.10%137K-43.22%180K250.71%1.24M13.42%431K-2.53%231K153.96%259K46.76%317K418.02%353K3,266.67%380K
Total other finance cost 1.73%-227K47.10%-137K43.22%-180K-250.71%-1.24M-13.42%-431K2.53%-231K-153.96%-259K-46.76%-317K-418.02%-353K-3,266.67%-380K
Other net income (expense)
Income before tax 15.79%-3.48M54.25%-3.63M55.70%-3.87M14.05%-24.22M58.64%-3.42M48.81%-4.14M-17.85%-7.94M-71.08%-8.73M-125.84%-28.18M-64.06%-8.26M
Income tax 00000-55K106.25%34K21K-534K10K
Net income 14.65%-3.48M54.44%-3.63M55.81%-3.87M12.39%-24.22M58.69%-3.42M49.49%-4.08M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M-64.26%-8.27M
Net income continuous Operations 14.65%-3.48M54.44%-3.63M55.81%-3.87M12.39%-24.22M58.69%-3.42M49.49%-4.08M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M-64.26%-8.27M
Minority interest income
Net income attributable to the parent company 14.65%-3.48M54.44%-3.63M55.81%-3.87M12.39%-24.22M58.69%-3.42M49.49%-4.08M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M-64.26%-8.27M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 14.65%-3.48M54.44%-3.63M55.81%-3.87M12.39%-24.22M58.69%-3.42M49.49%-4.08M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M-64.26%-8.27M
Basic earnings per share 41.18%-0.263.89%-0.2665.00%-0.2814.88%-2.0669.44%-0.2251.43%-0.34-33.33%-0.72-81.82%-0.8-101.67%-2.42-63.64%-0.72
Diluted earnings per share 41.18%-0.263.89%-0.2665.00%-0.2814.88%-2.0669.44%-0.2251.43%-0.34-33.33%-0.72-81.82%-0.8-101.67%-2.42-63.64%-0.72
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----------------Unqualified Opinion--
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Tesla
TSLA
+1.53%
MARA Holdings
MARA
+0.97%
MicroStrategy
MSTR
+0.86%
Apple
AAPL
-0.51%
Microsoft
MSFT
-0.57%

Unlock the Full List